Shares of Mirna Therapeutics Inc. (NASDAQ:MIRN) have been given a consensus rating of “Hold” by the six analysts that are covering the stock. Five research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $1.69.

A number of analysts have recently issued reports on MIRN shares. Leerink Swann downgraded Mirna Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $10.00 to $4.00 in a research report on Monday, August 15th. Citigroup Inc. downgraded Mirna Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $7.00 to $4.50 in a research report on Tuesday, August 16th. Oppenheimer Holdings Inc. lifted their price target on Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a research report on Tuesday, August 16th. Zacks Investment Research downgraded Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 18th. Finally, HC Wainwright started coverage on Mirna Therapeutics in a research report on Monday, September 12th. They set a “buy” rating and a $6.00 price target for the company.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/26/brokerages-set-mirna-therapeutics-inc-mirn-pt-at-1-69.html.

Shares of Mirna Therapeutics (NASDAQ:MIRN) opened at 1.54 on Monday. The firm’s market cap is $32.09 million. Mirna Therapeutics has a 12 month low of $1.12 and a 12 month high of $11.01. The stock’s 50 day moving average is $1.44 and its 200 day moving average is $3.13.

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Stock Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related stocks with our FREE daily email newsletter.